Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.

Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial

Abstract

Background Visceral and ectopic fat are key drivers of adverse cardiometabolic outcomes in obesity. We aimed to evaluate the effects of injectable liraglutide 3·0 mg daily on body fat distribution in adults with overweight or obesity without type 2 diabetes at high cardiovascular disease risk. Methods In this randomised, double-blind, placebo-controlled, phase 4, single centre trial, we enrolled community-dwelling adults, recruited from the University of Texas Southwestern Medical Center, with BMI of at least 30 kg/m 2 or BMI of at least 27 kg/m 2 with metabolic syndrome but without diabetes and randomly assigned them, in a 1:1 ratio, to 40 weeks of treatment with once-daily subcutaneous liraglutide 3·0 mg or placebo, in addition to a 500 kcal deficient diet and guideline-recommended physical activity counselling. The primary endpoint was percentage reduction in visceral adipose tissue (VAT) measured with MRI. All randomly assigned participants with a follow-up imaging assessment were included in efficacy analyses and all participants who received at least one dose of study drug were included in the safety analyses. The trial is registered on ClinicalTrials.gov: NCT03038620. Findings Between July 20, 2017 and Feb 21, 2020 from 235 participants assessed for eligibility, 185 participants were randomly assigned (n=92 liraglutide, n=93 placebo) and 128 (n=73 liraglutide, n=55 placebo) were included in the final analysis (92% female participants, 37% Black participants, 24% Hispan…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(21)00179-0

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Cited by

See all 227

Metadata

Authors
Neeland, I. J., Marso, S. P., Ayers, C. R., Lewis, B., Oslica, R., Francis, W., Rodder, S., Pandey, A., & Joshi, P. H.
Affiliations
  • Case Western Reserve University (US)
  • HCA Midwest Division (US)
  • The University of Texas Southwestern Medical Center (US)
  • Brigham and Women's Hospital (US)
Corresponding author
Neeland, Ian J
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2021-09
Volume
9
Issue
9
Pages
595-605
ISSN
2213-8587 (ISSN-L)
OpenAlex
W3191761156
Cited by
202
References
52
Citations by year
2026: 42 · 2025: 59 · 2024: 38 · 2023: 38 · 2022: 21 · 2021: 4
FWCI
14.74
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Sanofi
  • Pfizer
  • National Institute on Aging (1R03AG067960-01)
  • Gilead Sciences
  • AstraZeneca
  • National Aeronautics and Space Administration
  • Boston Scientific Corporation
  • GlaxoSmithKline
  • American Heart Association
  • Abbott Vascular
  • Merck
  • Novo Nordisk
  • Novartis
  • Amgen
  • Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
liraglutide, visceral adipose tissue, ectopic fat, obesity, overweight, metabolic syndrome, cardiovascular risk, GLP-1 receptor agonists, body fat distribution, weight loss, prediabetes, adverse events, gastrointestinal adverse effects, subcutaneous administration, MRI fat quantification, hypocaloric diet, physical activity counseling, prediabetes prevention, type 2 diabetes
MeSH terms
Liraglutide, Adult, Body Composition, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Obesity, Risk Factors, Treatment Outcome, Intra-Abdominal Fat, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. https://app.cochat.ai/papers/10.1016/s2213-8587(21)00179-0
The paper
Neeland, I. J., Marso, S. P., Ayers, C. R., Lewis, B., Oslica, R., Francis, W., Rodder, S., Pandey, A., & Joshi, P. H. (2021). Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(21)00179-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.